Fresenius Kabi is a leading global health care company that focuses on medicines and medical devices for critically and chronically ill patients inside and outside the hospital. Its APP brand of specialty injectable products is well known to hospitals and other health care providers in the United States. Fresenius Kabi provides a full line of critical care, anesthesia/analgesia, oncology and anti-infective products under the APP brand.
At A Glance
Fresenius Kabi USA
Customer Service Ordering
Toll-Free: (888) 386-1300
Toll-Free: (800) 551-7176
A leading supplier of multisource and branded injectable pharmaceutical products, primarily focused on the anesthesia/analgesia, anti-infective, critical care and oncology markets.
APP products are produced at multiple FDA-registered facilities located throughout the United States, Europe and Asia. To help further ensure that the company can reliably meet the needs of its customers, the global manufacturing capabilities of Fresenius Kabi have been utilized in times of great customer need.
What this ultimately means to health care providers and the patients they serve is that Fresenius Kabi USA has the commitment and resources to provide specialty injectable products that meet the highest quality standards.
Today, providing reliable access to quality specialty injectable products is more important than ever before. As part of a global company, Fresenius Kabi USA is positioned to provide high-quality products to its customers based on the following capabilities:
Together, these capabilities define what customers and patients expect and rely on from a leader focused on supporting the care of critically and chronically ill patients inside and outside the hospital.
In 2012, Fresenius Kabi USA was the second largest supplier of multisource products based on the number of units sold in the United States and Canada.1 The company ranks first in terms of the number of injectable drugs offered across four key therapeutic areas (Table).
There is a commitment to continually expand its already broad portfolio. Recently, Fresenius Kabi added Meropenem for Injection, USP (IV) and Imipenem and Cilastatin Injection, USP (IV) to its anti-infective portfolio; Acetylcysteine Injection, Tranexamic Acid Injection, Benztropine Mesylate Injection and Levetiracetam Injection to its critical care product line; and Oxaliplatin Injection, USP to its oncology portfolio.
Fresenius Kabi USA has the resources to maintain its commitment to providing quality essential medicines. The company’s processes, production capabilities and people demonstrate its commitment in action on a daily basis.
This corporate profile was reviewed and approved by The APP Brand of Specialty Injectable Products From Fresenius Kabi USA.